

# Philippe Robin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/249586/publications.pdf>

Version: 2024-02-01

78  
papers

1,691  
citations

377584

21  
h-index

355658

38  
g-index

82  
all docs

82  
docs citations

82  
times ranked

2267  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lung Ventilation/Perfusion Scintigraphy for the Screening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Which Criteria to Use?. <i>Frontiers in Medicine</i> , 2022, 9, 851935.	1.2	4
2	Radiopharmaceutical Labelling for Lung Ventilation/Perfusion PET/CT Imaging: A Review of Production and Optimization Processes for Clinical Use. <i>Pharmaceuticals</i> , 2022, 15, 518.	1.7	8
3	18F-Fluorodeoxyglucose positron emission/computed tomography for occult cancer among patients with unprovoked venous thromboembolism: What do we know?. <i>Thrombosis Research</i> , 2022, 213, S42-S45.	0.8	0
4	68Ga-Labelled Carbon Nanoparticles for Ventilation PET/CT Imaging: Physical Properties Study and Comparison with Technegas <sup>®</sup> . <i>Molecular Imaging and Biology</i> , 2021, 23, 62-69.	1.3	10
5	The Impact of Pulmonary Vascular Obstruction on the Risk of Recurrence of Pulmonary Embolism: A French Prospective Cohort. <i>Thrombosis and Haemostasis</i> , 2021, 121, 955-963.	1.8	5
6	Assessment of Image Quality and Lesion Detectability With Digital PET/CT System. <i>Frontiers in Medicine</i> , 2021, 8, 629096.	1.2	10
7	Convolutional neural networks for PET functional volume fully automatic segmentation: development and validation in a multi-center setting. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3444-3456.	3.3	15
8	[18F]FDG PET radiomics to predict disease-free survival in cervical cancer: a multi-scanner/center study with external validation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3432-3443.	3.3	32
9	Diagnostic value of positron-emission tomography textural indices for malignancy of 18F-fluorodeoxyglucose-avid adrenal lesions. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 65, 79-87.	0.4	5
10	Impact of the Age-Adjusted D-Dimer Cutoff to Exclude Pulmonary Embolism. <i>Circulation</i> , 2021, 143, 1828-1830.	1.6	18
11	Automatic delineation and quantification of pulmonary vascular obstruction index in patients with pulmonary embolism using Perfusion SPECT-CT: a simulation study. <i>EJNMMI Physics</i> , 2021, 8, 49.	1.3	2
12	Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18F-fluorocholine PET/CT: 1084 examinations. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2935-2950.	3.3	14
13	Fully Automated 68Ga-Labeling and Purification of Macroaggregated Albumin Particles for Lung Perfusion PET Imaging. <i>Frontiers in Nuclear Medicine</i> , 2021, 1, .	0.7	4
14	Performance of 18F-fluorodesoxyglucose positron-emission tomography/computed tomography for cancer screening in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis. <i>Thrombosis Research</i> , 2020, 194, 153-157.	0.8	3
15	Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2622-2628.	1.9	10
16	Ventilation/perfusion SPECT for the diagnosis of pulmonary embolism: A systematic review. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2910-2920.	1.9	11
17	Normal Dual Isotope V/Q SPECT Model for Monte-Carlo Studies. <i>Frontiers in Medicine</i> , 2020, 7, 461.	1.2	3
18	Evaluation of Venous Thromboembolism Recurrence Scores in an Unprovoked Pulmonary Embolism Population: A Post-hoc Analysis of the PADIS-PE trial. <i>American Journal of Medicine</i> , 2020, 133, e406-e421.	0.6	8

#	ARTICLE	IF	CITATIONS
19	V/Q SPECT for the Assessment of Regional Lung Function: Generation of Normal Mean and Standard Deviation 3-D Maps. <i>Frontiers in Medicine</i> , 2020, 7, 143.	1.2	7
20	Predictors of residual pulmonary vascular obstruction after pulmonary embolism: Results from a prospective cohort study. <i>Thrombosis Research</i> , 2020, 194, 1-7.	0.8	13
21	Correlation Between FDG Hotspots on Pre-radiotherapy PET/CT and Areas of HNSCC Local Relapse: Impact of Treatment Position and Images Registration Method. <i>Frontiers in Medicine</i> , 2020, 7, 218.	1.2	3
22	Integration of 18-FDG PET/CT in the Initial Work-Up to Stage Head and Neck Cancer: Prognostic Significance and Impact on Therapeutic Decision Making. <i>Frontiers in Medicine</i> , 2020, 7, 273.	1.2	6
23	Performance comparison of modified ComBat for harmonization of radiomic features for multicenter studies. <i>Scientific Reports</i> , 2020, 10, 10248.	1.6	109
24	Interobserver agreement of 18F-Fluorodeoxyglucose Positron-Emission Tomography combined with low-dose Computed Tomography for occult cancer screening in patients with unprovoked venous thromboembolism. <i>Thrombosis Research</i> , 2020, 188, 25-27.	0.8	2
25	Feasibility Study and Preliminary Results of Prognostic Value of Bone SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma to Abiraterone. <i>Frontiers in Medicine</i> , 2020, 6, 342.	1.2	5
26	Pulmonary perfusion by iodine subtraction maps CT angiography in acute pulmonary embolism: comparison with pulmonary perfusion SPECT (PASEP trial). <i>European Radiology</i> , 2020, 30, 4857-4864.	2.3	8
27	Predictors of Residual Pulmonary Vascular Obstruction after Pulmonary Embolism: results from a prospective cohort study. , 2020, , .		0
28	Prognostic value of textural indices extracted from pretherapeutic 18F FDG PET/CT in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 495-502.	0.9	36
29	Predictors for Residual Pulmonary Vascular Obstruction after Unprovoked Pulmonary Embolism: Implications for Clinical Practice – The PADIS-PE Trial. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1489-1497.	1.8	17
30	Evaluation of the predictive value of the bleeding prediction score VTE-BLEED for recurrent venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 364-371.	1.0	11
31	Diagnostic Value of FDG PET-CT Quantitative Parameters and Deauville-Like 5 Point-Scale in Predicting Malignancy of Focal Thyroid Incidentaloma. <i>Frontiers in Medicine</i> , 2019, 6, 24.	1.2	11
32	Inter-observer and segmentation method variability of textural analysis in pre-therapeutic FDG PET/CT in head and neck cancer. <i>PLoS ONE</i> , 2019, 14, e0214299.	1.1	23
33	Relationship between type of unprovoked venous thromboembolism and cancer location: An individual patient data meta-analysis. <i>Thrombosis Research</i> , 2019, 176, 79-84.	0.8	8
34	Time trend analysis of pulmonary embolism diagnosis with single-photon emission computed tomography ventilation/perfusion imaging. <i>Nuclear Medicine Communications</i> , 2019, 40, 576-582.	0.5	2
35	Quantitative analysis of technetium-99m-sestamibi uptake and washout in parathyroid scintigraphy supports dual mechanisms of lesion conspicuity. <i>Nuclear Medicine Communications</i> , 2019, 40, 469-476.	0.5	8
36	External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 864-877.	3.3	138

#	ARTICLE	IF	CITATIONS
37	SPECT V/Q for the diagnosis of pulmonary embolism: protocol for a systematic review and meta-analysis of diagnostic accuracy and clinical outcome. <i>BMJ Open</i> , 2018, 8, e022024.	0.8	10
38	Prediction of outcome using pretreatment 18F-FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 768-786.	3.3	193
39	Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial. <i>European Respiratory Journal</i> , 2018, 51, 1701202.	3.1	42
40	Revisiting occult cancer screening in patients with unprovoked venous thromboembolism. <i>Thrombosis Research</i> , 2018, 164, S7-S11.	0.8	9
41	Imaging and identification of brown adipose tissue on <sup>18</sup> F-NaF PET/CT scan. <i>Clinical Physiology and Functional Imaging</i> , 2018, 38, 186-191.	0.5	7
42	Diagnostic performance of <sup>18</sup> F-fluorodesoxyglucose positron emission/computed tomography and magnetic resonance imaging in detecting T1-T2 head and neck squamous cell carcinoma. <i>Laryngoscope</i> , 2018, 128, 378-385.	1.1	13
43	New developments and future challenges of nuclear medicine and molecular imaging for pulmonary embolism. <i>Thrombosis Research</i> , 2018, 163, 236-241.	0.8	34
44	Target definition in salvage postoperative radiotherapy for prostate cancer: 18F-fluorocholine PET/CT assessment of local recurrence. <i>Acta Oncologica</i> , 2018, 57, 375-381.	0.8	9
45	Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study. <i>Thrombosis Research</i> , 2018, 162, 104-109.	0.8	27
46	An aortic intra mural hematoma in ventilation/perfusion SPECT/CT. <i>Medicine (United States)</i> , 2018, 97, e12928.	0.4	0
47	Clinical interest of quantitative bone SPECT-CT in the preoperative assessment of knee osteoarthritis. <i>Medicine (United States)</i> , 2018, 97, e11943.	0.4	22
48	Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism: protocol for a systematic review and meta-analysis of individual participant data. <i>BMJ Open</i> , 2018, 8, e023939.	0.8	4
49	In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. <i>Thrombosis Research</i> , 2018, 171, 97-102.	0.8	6
50	Effect of occult cancer screening on mortality in patients with unprovoked venous thromboembolism. <i>Thrombosis Research</i> , 2018, 171, 92-96.	0.8	20
51	Feasibility of Systematic Respiratory-Gated Acquisition in Unselected Patients Referred for 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. <i>Frontiers in Medicine</i> , 2018, 5, 36.	1.2	8
52	A new SPECT/CT reconstruction algorithm: reliability and accuracy in clinical routine for non-oncologic bone diseases. <i>EJNMMI Research</i> , 2018, 8, 14.	1.1	21
53	Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. <i>Thrombosis Research</i> , 2017, 155, 6-9.	0.8	11
54	Scintigraphie pulmonaire pour suspicion d'embolie pulmonaire aiguë: État des lieux des pratiques en France en 2014. <i>Medecine Nucleaire</i> , 2017, 41, 55-63.	0.2	0

#	ARTICLE	IF	CITATIONS
55	Screening for cancer in patients with unprovoked venous thromboembolism; protocol for a systematic review and individual patient data meta-analysis. <i>BMJ Open</i> , 2017, 7, e015562.	0.8	14
56	Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2017, 39, 1155-1165.	0.9	16
57	Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. <i>Thrombosis Research</i> , 2017, 159, 48-51.	0.8	15
58	Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2017, 167, 410.	2.0	96
59	Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2184-2187.	1.9	22
60	Incremental diagnostic utility of systematic double-bed SPECT/CT for bone scintigraphy in initial staging of cancer patients. <i>Cancer Imaging</i> , 2017, 17, 16.	1.2	24
61	EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program. <i>EJNMMI Physics</i> , 2017, 4, 17.	1.3	14
62	Malignancy rate of focal thyroid incidentaloma detected by FDG PET-CT: results of a prospective cohort study. <i>Endocrine Connections</i> , 2017, 6, 413-421.	0.8	12
63	Clinical Validation of a Pixon-Based Reconstruction Method Allowing a Twofold Reduction in Planar Images Time of <sup>111</sup> In-Pentetreotide Somatostatin Receptor Scintigraphy. <i>Frontiers in Medicine</i> , 2017, 4, 143.	1.2	2
64	Performance of <sup>18</sup> F-fluorodesoxyglucose positron-emission tomography combined with low-dose computed tomography for cancer screening in patients with unprovoked venous thromboembolism. <i>PLoS ONE</i> , 2017, 12, e0178849.	1.1	3
65	Prognostic evaluation of percentage variation of metabolic tumor burden calculated by dual-phase <sup>18</sup> F-FDG PET-CT imaging in patients with head and neck cancer. <i>Head and Neck</i> , 2016, 38, E600-6.	0.9	35
66	An atypical sarcoidosis involvement in FDG PET/CT. <i>Medicine (United States)</i> , 2016, 95, e5700.	0.4	5
67	Does PET SUV Harmonization Affect PERCIST Response Classification?. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1699-1706.	2.8	31
68	Limited screening with versus without <sup>18</sup> F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. <i>Lancet Oncology</i> , 2016, 17, 193-199.	5.1	83
69	Additional value of combining low-dose computed tomography to V/Q SPECT on a hybrid SPECT-CT camera for pulmonary embolism diagnosis. <i>Nuclear Medicine Communications</i> , 2015, 36, 922-930.	0.5	34
70	Interest of chest X-ray in tailoring the diagnostic strategy in patients with suspected pulmonary embolism. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 643-648.	0.5	1
71	Diagnostic performance of FDG PET/CT to detect subclinical HNSCC recurrence 6 months after the end of treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 72-78.	3.3	29
72	Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 2072-2082.	3.3	81

#	ARTICLE	IF	CITATIONS
73	Performance of 18F fluoro-2-dÃ©soxy-D-glucose positron emission tomography/computed tomography for the diagnosis of venous thromboembolism. <i>Thrombosis Research</i> , 2015, 135, 31-35.	0.8	18
74	Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 659-667.	3.3	59
75	Safety of ventilation/perfusion single photon emission computed tomography for pulmonary embolism diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1957-1964.	3.3	34
76	18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1501-1510.	3.3	14
77	Prediction of HNSCC recurrence by using kinetic and volumetric FDG-PET parameters.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6081-6081.	0.8	0
78	V/Q SPECT Interpretation for Pulmonary Embolism Diagnosis: Which Criteria to Use?. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1077-1081.	2.8	41